Whilst many reports mention neurofibrillary tangle the thalamus in progressive supranuclear palsy. These findings have several implications. The caudal pathology in the thalamus in progressive supranuclear intralaminar thalamus appears to be one of three basal palsy, there has been little detailed regional analysis of ganglia sites commonly affected in both progressive the distribution and density of thalamic pathology in this supranuclear palsy and Parkinson's disease. These sites disease or in other parkinsonian syndromes. The caudal are the dopaminergic substantia nigra, the cholinergic intralaminar thalamic nuclei are the major thalamic pedunculopontine tegmental nucleus and, from our regulators of the caudate nucleus and putamen, areas results, the glutamatergic caudal intralaminar thalamus. known to be dysfunctional in progressive supranuclear
Introduction
Clinical features common to Parkinsonian disorders include who died between 1990 and 1996. This programme was bradykinesia, rigidity and postural instability (Litvan et al., approved by the institutional ethics committee in accordance 1997). Patients with Parkinson's disease also commonly with the National Health and Medical Research Council of exhibit resting tremor, while patients with progressive Australia and complied with the Declaration of Helsinki on supranuclear palsy (PSP) exhibit additional early falls and human experimentation. Consent of both patient and next of vertical gaze palsy (Litvan et al., 1997 ). Parkinson's disease kin were required for entry into the study. is characterized by the degeneration of brainstem basal The brain was removed at post-mortem, weighed, then ganglia structures associated with α-synuclein Lewy body fixed by suspension in 15% buffered formalin. After 2 weeks and Lewy neurite formation (Spillantini et al., 1997) . PSP is the brains were reweighed, the brainstem and cerebellum characterized by brainstem and basal ganglia degeneration removed, and the cerebrum was cut into 3 mm coronal slices associated with abundant formation of tau-positive neurousing a rotary slicer. Blocks were then taken from the frontal, fibrillary tangles (NFT) and neuropil threads (Litvan, 1998) .
motor, anterior cingulate and temporal cortices, hippocampus, The tau pathology of PSP can be differentiated from that of basal ganglia, midbrain, pons, medulla and cerebellum for Alzheimer's disease and Pick's disease by its subcortical paraffin-embedding and sectioning. Sections were stained distribution and the exclusive presence of exon 10 in the with haematoxylin-eosin, Bielschowsky silver stain and hyperphosphorylated tau isoforms found in the NFT (Pasquier immunohistochemistry for ubiquitin, as described previously and Delacourte, 1998; Sergeant et al., 1999) . (Harding and Halliday, 1998; Henderson et al., 2000) . The predilection of pathology for basal ganglia regions
Patients were selected using definitive neuropathological probably underlies many of the motor and cognitive deficits diagnosis according to published criteria (Hauw et al., 1994; present in Parkinsonian disorders (Litvan, 1998; Lozano Gelb et al., 1999) . Patients with neurodegenerative diseases et al., 1998). However, the normal expression of basal other than Parkinson's disease or PSP (e.g. Alzheimer's ganglia-related behaviours also requires an intact thalamus.
disease, corticobasal degeneration, multisystem atrophy) were In the original paper describing the clinical and pathological excluded. Six cases of PSP, nine cases of Parkinson's disease features of PSP, tangle formation was documented in the and ten controls were selected. Controls had no neurological thalamus, with the greatest concentration in the caudal or neuropathological abnormality. All patients selected were intralaminar nuclei (Steele et al., 1964) . The caudal intrafollowed longitudinally and were clinically reviewed at least laminar thalamic nuclei (parafascicular and centromedian 12 months before death with standardized scores for motor nuclei) have important connections with the basal ganglia, severity of disease (Hoehn and Yahr, 1967) . Patients with regulating the output of the caudate nucleus and putamen in dementia according to the Clinical Dementia Rating Scale concert with the dopaminergic substantia nigra (Percheron (Hughes et al., 1982) were excluded. Many of the cases et al., 1994) . Because of their functional similarity in basal reported have been analysed previously in studies of basal ganglia regulation, degeneration in both these regions may ganglia regions , be important for clinical disease expression. There have been 1996 There have been , 1997b Hardman and Halliday, 1999a, b;  Henderson no further studies of the caudal intralaminar thalamus in PSP, et al., 2000) . and before our recent analysis (Henderson et al., 2000) there All PSP patients studied met the NINDS-SPSP (National has been only limited information on these regions in Institute of Neurological Disorders and Stroke-Society for Parkinson's disease (Xuereb et al., 1990 (Xuereb et al., , 1991 . To determine Progressive Supranuclear Palsy, Inc.) criteria (Hauw et al. , whether these regions are selectively involved in 1994) for the clinical and pathological diagnosis of PSP. All parkinsonism, comparison with other thalamic nuclei is also had bradykinesia, rigidity, falls and/or supranuclear gaze required. The nearby mediodorsal and the anterior principal palsy, and little or no sustained response to levodopa. At the nuclei project largely to the frontal lobe and are considered time of death, two PSP patients had early bilateral limb signs major limbic nuclei (Engelborghs et al., 1998) , and are (Hoehn and Yahr stage 2-3) and four were severely disabled therefore selected as internal control nuclei for the specificity or were wheelchair-or bed-bound (Hoehn and Yahr stage 4-of degeneration. The present study describes the 5). All nine Parkinson's disease patients who were selected neurodegenerative changes within these thalamic nuclei in fulfilled the diagnostic criteria for Parkinson's disease (Gelb six patients with PSP compared with nine patients with et al., 1999) , were levodopa-responsive with bradykinesia Parkinson's disease and 10 age-matched, neurologically and rigidity, and six had tremor at rest. Parkinson's disease, four PSP patients and two controls died as described recently (Münkle et al., 1999; Henderson et al., 2000) , and the boundaries were plotted using an inteof pneumonia, four Parkinson's disease and six controls died of heart failure and one control and one PSP patient died of grated computerized microscope system (Neurolucida, MicroBrightField, Colchester, Vt., USA). The cross-sectional cancer. Agonal state was similar in all groups, and the postmortem delay was ഛ62 h in all patients (group mean Ϯ area of the nucleus within each section was calculated by the computer and the volume for each nucleus determined standard error of the mean: control, 20 Ϯ 4, Parkinson's disease, 31 Ϯ 4; PSP, 18 Ϯ 6). Further patient details are by multiplying the sum of the areas by the distance between the sections using Cavalieri's principle. There was Ͻ5% given in Table 1. variation in 10 repeat measures of the cross-sectional area for the smallest nucleus by the same investigator. There was Ͻ10% inter-rater variation in cross-sectional area and volume
Tissue preparation and analysis
After fixation and 3 mm coronal sectioning of the brain, the measurements of the same nuclei in four control cases. Therefore, boundaries of the nuclei delineated in this study thalamus was blocked from the mammillothalamic tract to the beginning of the pulvinar, cryoprotected in 30% sucrose are reliable and accurate. The total number of neurons and NFT within the in 0.1 M Tris-HCl buffer (pH 7.4) for 2 days, frozen to -20°C and serially sectioned on a Leica freezing microtome parafascicular nucleus (Pf) and the centromedian (CM), anterior principal (AP) and mediodorsal (MD) nuclei was at 50 µm intervals. Nine adjacent series of sections spaced 750 µm apart were taken and stained using (i) cresyl violet, quantified using the unbiased optical disector technique (Harding et al., 1994; Henderson et al., 2000) . Briefly, the (ii) haematoxylin-eosin, (iii) luxol fast blue, (iv) nickel peroxidase (Cullen, 1994) , and immunohistochemistry disector frame used for the neuronal counts was 100 ϫ 100 µm at a magnification of ϫ400. These disectors performed for (v) tau II [T5530, Sigma (St Louis, Mo., USA), diluted 1 : 10 000], (vi) ubiquitin (U5379; Sigma, were sampled in a grid array separated by 1 mm and the full section thickness was evaluated (50 µm). We have diluted 1 : 100), (vii) α-synuclein [18-0215, Zymed (San Francisco, Calif., USA), diluted 1 : 3000] and the calciumdemonstrated previously that the use of the full section thickness does not alter the disector calculations significantly binding proteins (viii) calbindin (C8666; Sigma, diluted 1 : 2000) and (ix) parvalbumin (P3171; Sigma, diluted (Harding et al., 1994) . The number of sections upon which disector frames were placed varied from 10 to 26 between 1 : 10 000). Routine immunohistochemistry was used with peroxidase visualization as described previously (Henderson cases. The number of disector frames sampled varied from 81 to 162 for Pf, 135 to 243 for CM, 43 to 103 for AP and et al., 2000) . A selection of sections were counterstained with cresyl violet. The specificity of the immunohistochemical 102-189 for MD. Nissl-stained neurons whose nucleolus fell entirely within the sampling frame or on one of each of three reaction was tested by omitting the primary antibody on test sections. No peroxidase reaction was observed.
adjacent inclusion borders (in the x, y and z planes) were counted. The number of neurons counted varied between 127 The criteria of Hirai and Jones (Hirai and Jones, 1989) were used for the boundaries of thalamic nuclei. Nuclear and 427 for the Pf nucleus, 79 and 255 for the CM nucleus, 74 and 174 for the AP nucleus and 162 and 306 for the MD boundaries were delineated in serial sections stained for different substances, including the calcium-binding proteins, nucleus. Repeated measures of the number of neurons within the sampling frames in multiple sections from multiple total number of remaining cells (ഛ10%) when compared with the limbic thalamic nuclei (ഛ1%). Despite these relative subjects consistently gave similar results, even between different investigators. Because of variations in the differences in concentration, the number of NFT in one thalamic region correlated with the number of NFT in the distribution and density of NFT between subjects, all tauimmunopositive NFT within the target region whose tip other regions (r 2 ϭ 0.55-0.97l) (Fig. 1K) . In contrast to the tau immunohistochemical staining, came into focus through the section were counted. Repeated measures of the number of tau-positive NFT within the same ubiquitin immunohistochemistry stained fewer cellular elements in either disease group. In PSP patients, ubiquitin sections from various subjects gave similar results between investigators. Neuronal density was estimated by dividing was found in a small proportion of extracellular, globose NFT. In Parkinson's disease patients, ubiquitin-and the total number of neurons counted by the total sample volume. The total number of neurons was estimated by α-synuclein-positive Lewy bodies and Lewy neurites were observed in the intralaminar nuclei (Fig. 1C, I and J). These multiplying the density of the neurons (coefficient of error range 0.03-0.11) by the volume of the region in which they pathological structures were more commonly observed in sections stained immunohistochemically for α-synuclein than were contained. The total number of NFT was estimated by summing the number counted per section in each region for ubiquitin. Many immunohistochemically stained pathological structures were axonal Lewy bodies (Fig. 1 ), (coefficient of error range 0.03-0.16) and multiplying by the sampling frequency (15).
although neuronal Lewy bodies as well as the entire neuronal cytoplasm contained α-synuclein immunoreactivity in a Statistical analysis was conducted using the Statview 5.0 program (Abacus Concepts, Berkeley, Calif., USA).
number of instances (Fig 1I and J) . Similar pathology was also observed in the limbic and motor thalamic nuclei, but Data are expressed as mean Ϯ standard error of the mean. For statistical analysis, a value of P Ͻ 0.05 was accepted to a lesser degree. Although neuronal Lewy body structures were relatively sparse, they were consistent with the as significant. Analysis of variance (ANOVA) was used to test for differences between the PSP, Parkinson's and pathological diagnosis of Parkinson's disease in these patients. control groups. Post hoc analysis using Fisher's protected least significant difference (PLSD) test was applied if differences were found. Regression analysis was used
Quantitation of volume and neuronal loss
The total volume of the thalamus in the PSP and Parkinson's to investigate any correlations between pathologies and disease duration. disease groups was not significantly different from that in the controls (ANOVA, P ϭ 0.15) ( Table 1 ). The MD and AP nuclei were readily delineated from surrounding thalamic Results nuclei ( Fig. 2A, D and G) and were composed of darkly There was no significant difference in age at death between stained, large neurons in all patients analysed (Fig. 2B , C, the patient and control groups (ANOVA, P ϭ 0.09; Table  E , F, H and I), with a neuronal density of~3200/mm 3 . There 1) or in disease duration between the patient groups was no significant difference in the volume of either the MD (ANOVA, P ϭ 0.40; Table 1 ). However, most of the PSP or the AP nucleus between the three groups (all ANOVA, patients had an earlier age of disease onset than the P Ͼ 0.10) ( Table 1) . Consistent with the lack of atrophy Parkinson's patients, as described in the literature found in these regions, there was no reduction in the total (Litvan, 1998) .
neuronal number compared with control values (ANOVA, P ϭ 0.12) ( Fig. 4A and B) . In controls, CM neurons were small and faintly stained for Nissl substance compared with the larger, more closely
Pathological lesions in the medial thalamus
As expected, tau immunohistochemistry revealed large packed and deeply stained Pf neurons ( Fig. 3B and C) . The neuronal density was~3600/mm 3 in the Pf and 2200/mm 3 in numbers of intracellular NFT in the medial thalamus of PSP patients, in contrast to controls and Parkinson's disease the CM nucleus. The Pf nucleus exhibited atrophy in both patient groups, the degree of atrophy being greatest in PSP patients (Fig. 1A, B and D-H) . The majority of tau-positive NFT were globose and significantly larger than glial tangles (45% relative to controls; Fisher's PLSD, P ϭ 0.011) ( Table  1) . Whilst atrophy of the Pf nucleus in PSP was, on average, (Fig. 1D) . Tau-positive glial tangles were mainly coiled bodies (Fig. 1D-H) or tufted-, star-or thorn-shaped astrocytes approximately twice that observed in Parkinson's disease, there was considerable individual variation such that this containing many processes. NFT density was increased in the intralaminar nuclei compared with the limbic thalamus difference just failed to reach significance (Fisher's PLSD, P ϭ 0.053). The Pf nucleus sustained obvious neuronal loss in PSP (Fig. 1A) . NFT were absent in the control and Parkinson's disease groups (Fig. 1B) . The number of NFT in both disease groups (Fig. 3B , E and H and Fig. 4C ) ( Table  1) . The volume and total neuronal number were strongly present in the PSP group was 30 500 Ϯ 6000 in the Pf, 33 000 Ϯ 4500 in the CM, 26 000 Ϯ 10 000 in the MD and correlated for the densely cellular Pf region (r 2 ϭ 0.84). On average, 30-50% of Pf nucleus neurons degenerated in 1500 Ϯ 500 in the AP nucleus. The caudal intralaminar nuclei showed a higher percentage of NFT relative to the Parkinson's disease (control versus Parkinson's disease, Fisher's PLSD, P ϭ 0.0031) and PSP (control versus PSP, 0.0050) ( (Fig. 3E and H) .
The PSP group also exhibited a 30% reduction in the P ϭ 0.44) ( Table 1) . While atrophy of the CM was consistently found only in the PSP group, neuronal loss within the CM volume of the CM (PSP versus control, Fisher's PLSD, P ϭ was similar in the two patient groups (average neuronal loss using the Hoehn and Yahr score and the magnitude of the degeneration in either the Pf or the CM nucleus in the disease compared with controls, 40-55%) (Table 1 ; Fig. 3C , F and I; Fig. 4D ). Thus, the neuronal degeneration within the groups (Fig. 5) . Similar atrophy and cell loss were found irrespective of whether Parkinson's disease or PSP patients intralaminar thalamic nuclei was similar in the two disease groups (Fisher's PLSD: control versus Parkinson's disease, had mild or more severe disease (Fig. 5) . Similarly, no relationship was found between disease duration and the P Ͻ 0.0001; control versus PSP, P Ͻ 0.001; Parkinson's disease versus PSP, P ϭ 0.12) (Fig. 4C and D) , even though degree of cell loss in the patient groups (Pf, r 2 ϭ 0.12; CM, r 2 ϭ 0.39). The degree of neuronal loss in these nuclei was considerably more atrophy occurred in the CM in PSP. This suggests additional degeneration of CM neuropil in the PSP similar regardless of these clinical parameters and whether tremor was present or absent. In contrast, there was a negative cases. There were no significant correlations between the number of neurons in one thalamic region and the number correlation between NFT number and disease duration (r 2 ϭ -0.63 to -0.97), in that the longer the disease was present found in another.
the fewer NFT were found within all thalamic nuclei (Fig. 5) .
Correlations between pathologies and clinical variables Discussion
The present study describes previously under-recognized In both disease groups, characteristic pathology was found within regions of neurodegeneration (Fig. 1A-J) . However, degeneration of the caudal intralaminar thalamus in both PSP and Parkinson's disease. For both diseases, the characteristic in PSP patients, characteristic pathology was also found in regions without considerable neurodegeneration, suggesting disease pathology (NFT or Lewy bodies) was observed throughout the thalamus. Although the pathological substrate a more widespread disease mechanism. In the PSP patients analysed, ഛ1% of neurons in the MD and AP contained differed between these Parkinsonian disorders, the thalamic regions with neuronal loss were the same. In both Parkinson's NFT, whereas~10% of the remaining CM and Pf neurons contained NFT. disease and PSP, prominent cell loss was restricted to the caudal intralaminar nuclei (averaging 40-55% cell loss). This Comparisons between clinical and cellular variables revealed no significant relationship between disease severity cell loss was very selective as pathology was found in the nucleus and the non parvalbumin-containing neurons in the CM nucleus (Henderson et al., 2000) ]. In PSP, atrophy was also observed in the CM nucleus, probably reflecting the additional degeneration of basal ganglia output nuclei, resulting in thalamic deafferentation (Hardman et al., 1997b; Litvan, 1998; Hardman and Halliday, 1999b) . Our findings suggest that, in addition to the dopaminergic substantia nigra, the caudal intralaminar thalamus may be an important effector in the genesis of common extrapyramidal symptoms in Parkinsonian disorders, even though PSP and Parkinson's disease have different underlying pathologies. Whilst many studies have reported the presence of NFT pathology in the thalamus in PSP (Steele et al., 1964; Lantos, 1994; Matsumoto et al., 1996) , there has been little detailed regional analysis of their distribution and density. In our patients with pathology in the typical basal ganglion and brainstem predilection sites Hardman et al., 1996 Hardman et al., , 1997b Hardman and Halliday, 1999a, b) , tau pathology also concentrated in the caudal intralaminar nuclei of the thalamus. It has been proposed that NFT formation is an index of cell loss Braak, 1991, 1998; Lantos, 1994) . Interestingly, we found that NFT accounts for only a small proportion of cell loss (ഛ10%) in these thalamic regions in PSP. This occurred primarily because of the loss of NFT over the duration of the disease, suggesting clearance of these structures during the typical clinical course of the disease (which is shorter than for many other neurodegenerative conditions). This NFT data in PSP differs significantly from what is thought to occur in Alzheimer's disease, where NFT remain in the extracellular space for decades after cell death (Braak and Braak, 1998) , enabling their use in pathological grading (Braak and Braak, 1991) . Our data suggest that NFT in PSP cannot be utilized in the same way. Considerable variability in the distribution of NFT pathology in PSP cases has been noted previously (Lantos, independently of NFT formation, possibly via an alternative pathogenic mechanism. The lack of an association between limbic thalamus without neurodegeneration. To our knowledge, no studies have examined these thalamic regions the degree of cell loss and NFT formation further supports this concept (and cell loss was not correlated with disease in detail in PSP. A previous study in Parkinson's disease observed some cell loss in the CM, but it was proposed that duration). In idiopathic Parkinson's disease there was also prominent this degeneration may be related to ageing (Xuereb et al., 1991) . Our results suggest otherwise (see also Henderson cell loss in the intralaminar thalamus (see also Henderson et al., 2000) . Lewy bodies were found in the thalamus, et al., 2000) and show that similar selective degeneration of the thalamus occurs in both Parkinson's disease and PSP, consistent with their location in degenerating brainstem regions in this disease (Daniel, 1995; Gelb et al., 1999) . In the which are movement disorders with overlapping extrapyramidal symptoms. In Parkinson's disease, we have shown brainstem, Lewy bodies are typically rounded, eosinophilic, intracytoplasmic inclusion bodies, whereas those present in recently that neuronal degeneration occurs principally in neurons differentially expressing calcium-binding proteins the cerebral cortex are better seen with immunohistochemistry for α-synuclein or ubiquitin (Daniel, 1995; Forno, 1996 ; [affecting both the parvalbumin-containing neurons in the Pf Spillantini et al., 1997) . The Lewy bodies observed in the poor treatment outcomes in the initial stages of the disease. Together, these data suggest that the caudal intralaminar nuclei thalamus in the present study were more typical of those found in cortical regions since they were pale-staining in may be affected towards the beginning of the clinical course of each disease. haematoxylin-eosin but intensely immunoreactive for α-synuclein, even without formic acid pretreatment (Takeda In conclusion, we have identified substantial degeneration of the caudal intralaminar nuclei in both PSP and Parkinson's et al., 1998) . Interestingly, Lewy body pathology was rarely observed when ubiquitin immunohistochemistry was disease. While the characteristic pathologies specific to these diseases are observed within the thalamus, the proportion of performed on parallel series of thick sections. This may explain why few previous studies have reported such thalamic remaining neurons affected by these pathologies is low. This may indicate additional (possibly common) cellular pathology (Fearnley and Lees, 1994; Braak et al., 1996) .
Our results indicate that the caudal intralaminar thalamus mechanisms responsible for the cell loss in these regions in both disorders. Loss of the caudal intralaminar nuclei together appears to be one of three basal ganglia sites commonly affected in both PSP and Parkinson's disease. The two sites with the dopaminergic substantia nigra could contribute to the development of parkinsonism by disruption of striatal outputs identified previously are the dopaminergic substantia nigra (Fearnley and Lees, 1991; Halliday et al., 1996; and sensorimotor processing through the Nauta-Mehler loop (Nauta and Mehler, 1966; Sadikot et al., 1992) . Our work et al., 1997a) and the cholinergic pedunculopontine tegmental nucleus (Hirsch et al., 1987; Jellinger, 1988; Gai et al., suggests that non-dopaminergic mechanisms are also important in the evolution of PSP and Parkinson's disease. 1991). The dopaminergic substantia nigra is thought to be pivotal to these diseases, while the role of the pedunculopontine tegmental nucleus is as yet unclear. The involvement of the caudal intralaminar nucleus can be inferred from its
